EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Factors Influencing Discontinuation of Clazosentan Therapy in Elderly Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study from a Japanese Single Center

Tatsushi Mutoh iD, Hiroaki Aono, Wataru Seto, Takehiro Kimoto, Ryota Tochinai, Junta Moroi, Tatsuya Ishikawa

Medical Science Monitor · 2024

DOI: 10.12659/msm.943303 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Medical Science Monitor, 2024. Verfasst von Tatsushi Mutoh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Neurology, Research Institute for Brain and Blood Vessels, Akita Cerebrospinal and Cardiovascular Center, Akita, Japan. Hauptthemen laut MEDLINE: Subarachnoid Hemorrhage, Vasospasm, Intracranial, Dioxanes, Pyridines. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Clazosentan is an endothelin receptor antagonist approved in Japan for preventing cerebral vasospasm and vasospasm-associated cerebral ischemia and infarction. This study included elderly patients aged ≥75 years with aneurysmal subarachnoid hemorrhage (SAH) and aimed to evaluate the factors associated with discontinuing anti-vasospasm therapy with clazosentan. MATERIAL AND METHODS In this single-center retrospective observational study, we extracted diagnostic and therapeutic work-up data of consecutive 40 patients with SAH treated with clazosentan infusion (10 mg/h) as first-line anti-vasospasm therapy between May 2022 and August 2023. Patient data were compared between the discontinued and completed groups, and related factors for the discontinuation were further analyzed. RESULTS Clazosentan was discontinued in 22% (n=9) of patients due to intolerable dyspnea accompanied by hypoxemia at 5±3 days after therapy initiation, in which 44% (n=4) were elderly (≥75 years). Patients who discontinued clazosentan therapy showed significantly lower urine volumes compared with those who completed the therapy (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Subarachnoid HemorrhageVasospasm, IntracranialDioxanesPyridinesPyrimidinesSulfonamidesAgedHumansRetrospective StudiesJapanTetrazolesHypoxia

Substanzen

clazosentanTetrazolesDioxanesPyridinesPyrimidinesSulfonamides

Autor:innen und Institutionen

  • Department of Surgical Neurology, Research Institute for Brain and Blood Vessels, Akita Cerebrospinal and Cardiovascular Center, Akita, Japan.
  • Department of Pharmaceutics, Akita Cerebrospinal and Cardiovascular Center, Akita, Japan.
  • Department of Veterinary Pathophysiology and Animal Health, Graduate School of Agriculture and Life Sciences, the University of Tokyo, Tokyo, Japan.

ORCID-Profile: Tatsushi Mutoh

Zitieren

APA

Mutoh, T., Aono, H., Seto, W., Kimoto, T., Tochinai, R., Moroi, J., & Ishikawa, T. (2024). Factors Influencing Discontinuation of Clazosentan Therapy in Elderly Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study from a Japanese Single Center. Medical Science Monitor. https://doi.org/10.12659/msm.943303

Vancouver

Mutoh T, Aono H, Seto W, Kimoto T, Tochinai R, Moroi J, et al. Factors Influencing Discontinuation of Clazosentan Therapy in Elderly Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study from a Japanese Single Center. Medical Science Monitor. 2024. doi:10.12659/msm.943303

BibTeX
@article{Mutoh2024,
  author = {Mutoh, Tatsushi and Aono, Hiroaki and Seto, Wataru and Kimoto, Takehiro and Tochinai, Ryota and Moroi, Junta and Ishikawa, Tatsuya},
  title = {Factors Influencing Discontinuation of Clazosentan Therapy in Elderly Patients with Aneurysmal Subarachnoid Hemorrhage: A Retrospective Study from a Japanese Single Center},
  journal = {Medical Science Monitor},
  year = {2024},
  doi = {10.12659/msm.943303}
}
Kostenlos starten →